Liver cancer: Approaching a personalized care

Jordi Bruix, KwangHyub Han, Gregory Gores, Josep Maria Llovet, Vincenzo Mazzaferro

Research output: Contribution to journalReview article

104 Citations (Scopus)

Abstract

The knowledge and understanding of all aspects of liver cancer [this including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA)] have experienced a major improvement in the last decades. New laboratory technologies have identified several molecular abnormalities that, at the very end, should provide an accurate stratification and optimal treatment of patients diagnosed with liver cancer. The seminal discovery of the TP53 hotspot mutation [1,2] was an initial landmark step for the future classification and treatment decision using conventional clinical criteria blended with molecular data. At the same time, the development of ultrasound, computed tomography (CT) and magnetic resonance (MR) has been instrumental for earlier diagnosis, accurate staging and treatment advances. Several treatment options with proven survival benefit if properly applied are now available. Major highlights include: i) acceptance of liver transplantation for HCC if within the Milan criteria [3], ii) recognition of ablation as a potentially curative option [4,5], iii) proof of benefit of chemoembolization (TACE), [6] and iv) incorporation of sorafenib as an effective systemic therapy [7]. These options are part of the widely endorsed BCLC staging and treatment model (Fig. 1) [8,9]. This is clinically useful and it will certainly keep evolving to accommodate new scientific evidence. This review summarises the data which are the basis for the current recommendations for clinical practice, while simultaneously exposes the areas where more research is needed to fulfil the still unmet needs (Table 1).

Original languageEnglish
Pages (from-to)S144-S156
JournalJournal of Hepatology
Volume62
Issue numberS1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Liver Neoplasms
Hepatocellular Carcinoma
Therapeutics
Cholangiocarcinoma
Liver Transplantation
Early Diagnosis
Magnetic Resonance Spectroscopy
Tomography
Technology
Mutation
Survival
Research

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Bruix, J., Han, K., Gores, G., Llovet, J. M., & Mazzaferro, V. (2015). Liver cancer: Approaching a personalized care. Journal of Hepatology, 62(S1), S144-S156. https://doi.org/10.1016/j.jhep.2015.02.007
Bruix, Jordi ; Han, KwangHyub ; Gores, Gregory ; Llovet, Josep Maria ; Mazzaferro, Vincenzo. / Liver cancer : Approaching a personalized care. In: Journal of Hepatology. 2015 ; Vol. 62, No. S1. pp. S144-S156.
@article{6bf7cf83a27e4aab883aeb14af59aa56,
title = "Liver cancer: Approaching a personalized care",
abstract = "The knowledge and understanding of all aspects of liver cancer [this including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA)] have experienced a major improvement in the last decades. New laboratory technologies have identified several molecular abnormalities that, at the very end, should provide an accurate stratification and optimal treatment of patients diagnosed with liver cancer. The seminal discovery of the TP53 hotspot mutation [1,2] was an initial landmark step for the future classification and treatment decision using conventional clinical criteria blended with molecular data. At the same time, the development of ultrasound, computed tomography (CT) and magnetic resonance (MR) has been instrumental for earlier diagnosis, accurate staging and treatment advances. Several treatment options with proven survival benefit if properly applied are now available. Major highlights include: i) acceptance of liver transplantation for HCC if within the Milan criteria [3], ii) recognition of ablation as a potentially curative option [4,5], iii) proof of benefit of chemoembolization (TACE), [6] and iv) incorporation of sorafenib as an effective systemic therapy [7]. These options are part of the widely endorsed BCLC staging and treatment model (Fig. 1) [8,9]. This is clinically useful and it will certainly keep evolving to accommodate new scientific evidence. This review summarises the data which are the basis for the current recommendations for clinical practice, while simultaneously exposes the areas where more research is needed to fulfil the still unmet needs (Table 1).",
author = "Jordi Bruix and KwangHyub Han and Gregory Gores and Llovet, {Josep Maria} and Vincenzo Mazzaferro",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.jhep.2015.02.007",
language = "English",
volume = "62",
pages = "S144--S156",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "S1",

}

Bruix, J, Han, K, Gores, G, Llovet, JM & Mazzaferro, V 2015, 'Liver cancer: Approaching a personalized care', Journal of Hepatology, vol. 62, no. S1, pp. S144-S156. https://doi.org/10.1016/j.jhep.2015.02.007

Liver cancer : Approaching a personalized care. / Bruix, Jordi; Han, KwangHyub; Gores, Gregory; Llovet, Josep Maria; Mazzaferro, Vincenzo.

In: Journal of Hepatology, Vol. 62, No. S1, 01.01.2015, p. S144-S156.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Liver cancer

T2 - Approaching a personalized care

AU - Bruix, Jordi

AU - Han, KwangHyub

AU - Gores, Gregory

AU - Llovet, Josep Maria

AU - Mazzaferro, Vincenzo

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The knowledge and understanding of all aspects of liver cancer [this including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA)] have experienced a major improvement in the last decades. New laboratory technologies have identified several molecular abnormalities that, at the very end, should provide an accurate stratification and optimal treatment of patients diagnosed with liver cancer. The seminal discovery of the TP53 hotspot mutation [1,2] was an initial landmark step for the future classification and treatment decision using conventional clinical criteria blended with molecular data. At the same time, the development of ultrasound, computed tomography (CT) and magnetic resonance (MR) has been instrumental for earlier diagnosis, accurate staging and treatment advances. Several treatment options with proven survival benefit if properly applied are now available. Major highlights include: i) acceptance of liver transplantation for HCC if within the Milan criteria [3], ii) recognition of ablation as a potentially curative option [4,5], iii) proof of benefit of chemoembolization (TACE), [6] and iv) incorporation of sorafenib as an effective systemic therapy [7]. These options are part of the widely endorsed BCLC staging and treatment model (Fig. 1) [8,9]. This is clinically useful and it will certainly keep evolving to accommodate new scientific evidence. This review summarises the data which are the basis for the current recommendations for clinical practice, while simultaneously exposes the areas where more research is needed to fulfil the still unmet needs (Table 1).

AB - The knowledge and understanding of all aspects of liver cancer [this including hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA)] have experienced a major improvement in the last decades. New laboratory technologies have identified several molecular abnormalities that, at the very end, should provide an accurate stratification and optimal treatment of patients diagnosed with liver cancer. The seminal discovery of the TP53 hotspot mutation [1,2] was an initial landmark step for the future classification and treatment decision using conventional clinical criteria blended with molecular data. At the same time, the development of ultrasound, computed tomography (CT) and magnetic resonance (MR) has been instrumental for earlier diagnosis, accurate staging and treatment advances. Several treatment options with proven survival benefit if properly applied are now available. Major highlights include: i) acceptance of liver transplantation for HCC if within the Milan criteria [3], ii) recognition of ablation as a potentially curative option [4,5], iii) proof of benefit of chemoembolization (TACE), [6] and iv) incorporation of sorafenib as an effective systemic therapy [7]. These options are part of the widely endorsed BCLC staging and treatment model (Fig. 1) [8,9]. This is clinically useful and it will certainly keep evolving to accommodate new scientific evidence. This review summarises the data which are the basis for the current recommendations for clinical practice, while simultaneously exposes the areas where more research is needed to fulfil the still unmet needs (Table 1).

UR - http://www.scopus.com/inward/record.url?scp=84937517958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937517958&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2015.02.007

DO - 10.1016/j.jhep.2015.02.007

M3 - Review article

C2 - 25920083

AN - SCOPUS:84937517958

VL - 62

SP - S144-S156

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - S1

ER -